Irinotecan Liposomal Injection [Onivyde]

DRUG2 trials

Sponsors

AIO-Studien-gGmbH, Seoul National University Hospital

Conditions

Locally Advanced Pancreatic CancerMetastatic Pancreatic CancerPancreatic Cancer

Phase 2

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

RecruitingNCT04371224

Seoul National University HospitalPancreatic Cancer

Start: 2020-06-23End: 2025-12-31Target: 200Updated: 2024-04-19

Phase 3

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

CompletedNCT03468335

AIO-Studien-gGmbHLocally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer

Start: 2018-03-31End: 2022-05-31Updated: 2025-04-17

Related Papers

Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

2025-10-14

An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial

Molecular Cancer2025-07-22

A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216).

Journal of Clinical Oncology2025-05-28

Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL).

Journal of Clinical Oncology2025-01-27

Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Journal of Clinical Oncology2023-01-24

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.

Journal of Clinical Oncology2022-01-193 citations